|
End-of-day quote
Nasdaq
2026-08-14
|
5-day change | 1st Jan Change | ||
| 1.700 USD | +0.59% |
|
0.00% | -81.17% |
| 08-11 | EnGene Therapeutics Inc. - Special Call | |
| 07-16 | EnGene Therapeutics Initiates Planned BLA Submission For Detalimogene Voraplasmid And Provides Updates On LEGEND Phase 2 Trial | CI |
Chart: Technical Analysis
Stock exchange
Nasdaq
ENGN 1.700 $
+0.59%
1.56M
$
| Markets | Price | Change | Volumes | ||
|---|---|---|---|---|---|
Nasdaq
| ENGN | 1.700USD | +0.59% | 1.56M $ | |
CBOE
| ENGN | 1.855USD | +8.48% | 36.4K $ | |
|
Deutsche Boerse AG
| S0N0 | 1.430EUR | 0.00% | 0 € |
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Neutral | Bearish | Bearish |
| Resistance | 1.93 | 3.94 | 4.24 |
| Spread/Res. | -11.92% | -56.85% | -59.91% |
| Spread/Supp. | +0.59% | +18.06% | +13.33% |
| Support | 1.69 | 1.44 | 1.5 |
MarketScreener's Technical Analysis Ratings
| Short Term Timing | |
|---|---|
| Middle Term Timing | |
| Long Term Timing | |
| RSI | |
| Bollinger Spread | |
| Unusual Volumes |
- Stock Market
- Stocks
- ENGN Stock
- Charts enGene Therapeutics Inc.
Select your edition
All financial news and data tailored to specific country editions
